Establishment and validation of a risk prediction model incorporating concentrations of linezolid and its metabolite PNU142300 for linezolid-induced thrombocytopenia

• DOI: 10.1093/jac/dkad191
• Publication Date: 2023-06-21T10:28:38Z
• Authors: Jinhui Xu; Jian Lu; Yunlong Yuan; Lufen Duan; Lu Shi; Fang Chen; Yifei Cao; Guangjuan Xu; Zongtai Feng; Lan Li; Hongzhi Xue; Jiantong Sun; Qin Zhou; Zhiwei Zhuang; Lian Tang
• Keywords: Cmin; Linezolid; Cumulative incidence

Linezolid-induced thrombocytopenia is the main factor restricting clinical application of linezolid.To investigate relationship between PNU-14230 concentration and linezolid-induced further develop validate a risk model for predicting thrombocytopenia.A regression was constructed to predict occurrence thrombocytopenia, externally validated. The predictive performance evaluated by receiver operating characteristic curve Hosmer-Lemeshow test. Linezolid Cmin PNU-142300 concentrations were compared different kidney function groups. Kaplan-Meier method used estimate difference in cumulative incidence among patients.In derivation (n = 221) validation 158) cohorts, 28.5% 24.1% critically ill patients developed thrombocytopenia. Logistic analysis indicated that independent factors linezolid Cmin, concentration, baseline platelet count, renal insufficiency (RI) continuous venovenous haemofiltration (CVVH). AUC 0.901, good (P 0.633). also showed discrimination (AUC 0.870) calibration 0.282) external cohort. Compared with normal patients, RI CVVH had higher < 0.001) 0.001).PNU142300 as well might identify at prediction development. Concentrations accumulated CVVH.